• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Akari Therapeutics plc (Amendment)

    2/14/23 4:05:33 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email
    SC 13G/A 1 ea173418-13ga4patel_akari.htm AMENDMENT NO. 4 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

     

    Akari Therapeutics, PLC

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0001 per share

    (represented by American Depositary Shares)

    (Title of Class of Securities)

     

    00972G108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 2 of 5

     

    1

    NAME OF REPORTING PERSON

     

    Samir R. Patel

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH

    5

    SOLE VOTING POWER

     

    7,862,047 shares(1)

    6

    SHARED VOTING POWER

     

    0 shares

    7

    SOLE DISPOSITIVE POWER

     

    7,862,047 shares(1)

    8

    SHARED DISPOSITIVE POWER

     

    0 shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,862,047 shares(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1)Comprised of Ordinary Shares represented by American Depositary Shares. Each American Depositary Share reported represents 100 Ordinary Shares. Includes warrants to purchase up to 2,238,748 American Depositary Shares. Does not include warrants to purchase up to 2,011,252 American Depositary Shares which are not exercisable within the next 60 days and for which the reporting person disclaims beneficial ownership.

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 3 of 5

     

    Item 1(a). Name of Issuer

     

    Akari Therapeutics, PLC (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices

     

    75/76 Wimpole Street

    London W1G 9RT

    United Kingdom

     

    Item 2(a). Name of Person Filing

     

    Samir R. Patel (the “Reporting Person”)

     

    Item 2(b). Address of Principal Business Office or, if None, Residence

     

    The address of the principal business and principal office of the Reporting Person is:

     

    1701 Chicon St., Austin, Texas, 78702

     

    Item 2(c). Citizenship

     

    Samir R. Patel is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities

     

    Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares, each of which represents 100 Ordinary Shares)

     

    Item 2(e). CUSIP Number

     

    00972G108

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 4 of 5

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership

     

    With respect to the beneficial ownership of the Reporting Person, see Items 5 through 11 of the cover pages to this Schedule 13G, which are incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

      /s/ Samir R. Patel
      Samir R. Patel

     

     

     

     

     

     

    Get the next $AKTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX

    DatePrice TargetRatingAnalyst
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of AkariRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed

    8/14/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Releases Virtual Investor "What This Means" Segment

    Watch the "What This Means" video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company's ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for c

    7/29/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

    PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator,

    7/23/25 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    SEC Filings

    View All

    Akari Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    8/19/25 8:00:23 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akari Therapeutics plc

    10-Q - Akari Therapeutics Plc (0001541157) (Filer)

    8/13/25 5:01:23 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Akari Therapeutics plc

    EFFECT - Akari Therapeutics Plc (0001541157) (Filer)

    8/1/25 12:15:28 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

    Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

    5/1/25 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

    Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

    4/16/25 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Financials

    Live finance-specific insights

    View All

    Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

    BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

    11/8/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

    BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

    10/15/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

    Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

    6/5/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    6/20/24 7:30:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Akari Therapeutics plc

    SC 13D - Akari Therapeutics Plc (0001541157) (Subject)

    6/18/24 4:15:30 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care